{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:38:53Z","timestamp":1792031933203,"version":"4.4.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Enalapril is an angiotensin-converting enzyme (ACE) inhibitor (ACEi) which is widely used in the management of (paediatric) hypertension and heart failure (HF). There is a significant interindividual variability in the patient's response to enalapril that is not completely understood. Therefore, we aimed to examine the potential of metabolic profiling for stratifying paediatric patients with HF due to congenital heart disease (CHD) in terms of treatment response to enalapril. Additionally, we investigated metabolic profiles in CHD patients and healthy controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>CHD patients aged 0\u20136 years of age who previously participated in a multi-centre and multinational pharmacokinetic safety bridging study of enalapril were included. Patients were defined as responder when aldosterone levels decreased after a single administration of enalapril. Non-responders were those with an increase in their aldosterone levels. We applied an untargeted mass spectrometry-based metabolomics approach on serum. By using both supervised and unsupervised learning algorithms, we compared metabolic profiles between responders and non-responders as well as between patients and age and sex matched healthy controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 63 patients were included with a median age of 132 (IQR 54\u2013211) days and 46 controls [97 (63\u2013160) days]. 41 of 63 patients responded to enalapril therapy. Their baseline characteristics were similar to non-responders (<jats:italic>n<\/jats:italic>\u2009=\u200922). A total of 1,820 unique features were identified. Responders were distinguished from non-responders using a supervised learning algorithm based on 94 features (<jats:italic>p<\/jats:italic>\u2009=\u20090.05). Furthermore, metabolic profiles could distinguish between patients and controls based on an unsupervised learning algorithm which revealed 278 relevant features (<jats:italic>p<\/jats:italic>\u2009=\u20090.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These are the first data to demonstrate a clear metabolic signature in children with CHD using ACEi. We identified metabolites whose concentrations were both associated with ACEi response and HF. This indicates more severe HF in patients with more profound treatment response. Our results will therefore allow further studies aiming at disentangling variability in ACEi treatment response.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1530063","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:32:00Z","timestamp":1745818320000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Untargeted metabolic analysis in serum samples reveals metabolic signature in children with congenital heart failure on enalapril therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"N. J. L.","family":"Smeets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. N.","family":"van Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J. M.","family":"Jans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dalinghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Laer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bajcetic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Male","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. N.","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S0735-1097(00)00673-2","article-title":"Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study","volume":"36","author":"Mori","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1161\/01.CIR.88.5.2277","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (studies of left ventricular dysfunction) investigators","volume":"88","author":"Konstam","year":"1993","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10557-017-6733-2","article-title":"The pharmacogenomic and metabolomic predictors of ACE inhibitor and angiotensin II receptor blocker effectiveness and safety","volume":"31","author":"Flaten","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2165\/00003495-199243030-00005","article-title":"Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension","volume":"43","author":"Todd","year":"1992","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2125.1987.tb03069.x","article-title":"The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure","volume":"23","author":"Dickstein","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/00005344-198507000-00023","article-title":"Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension","volume":"7","author":"Schwartz","year":"1985","journal-title":"J Cardiovasc Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1365-2125.1986.tb02823.x","article-title":"Pharmacokinetics of enalapril in normal subjects and patients with renal impairment","volume":"21","author":"Kelly","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/cpdd.129","article-title":"Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets","volume":"3","author":"Moffett","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1161\/01.HYP.31.5.1088","article-title":"Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives","volume":"31","author":"Weir","year":"1998","journal-title":"Hypertension"},{"key":"B10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11306-019-1601-7","article-title":"Predicting response to lisinopril in treating hypertension: a pilot study","volume":"15","author":"Sonn","year":"2019","journal-title":"Metabolomics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0153163","DOI":"10.1371\/journal.pone.0153163","article-title":"The pharmacogenetic footprint of ACE inhibition: a population-based metabolomics study","volume":"11","author":"Altmaier","year":"2016","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2020.08.005","article-title":"Pharmacology of enalapril in children: a review","volume":"25","author":"Smeets","year":"2020","journal-title":"Drug Discov Today"},{"key":"B13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/BF00442742","article-title":"The renin-angiotensin-aldosterone system in infancy and childhood in basal conditions and after stimulation","volume":"143","author":"Fiselier","year":"1984","journal-title":"Eur J Pediatr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100393","DOI":"10.1016\/j.conctc.2019.100393","article-title":"Orodispersible minitablets of enalapril for use in children with heart failure (LENA): rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study","volume":"15","author":"Bajcetic","year":"2019","journal-title":"Contemp Clin Trials Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061163","article-title":"Enalapril and enalaprilat pharmacokinetics in children with heart failure due to dilated cardiomyopathy and congestive heart failure after administration of an orodispersible enalapril minitablet (LENA-studies)","volume":"14","author":"Laeer","year":"2022","journal-title":"Pharmaceutics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00246-012-0306-8","article-title":"The ross classification for heart failure in children after 25 years: a review and an age-stratified revision","volume":"33","author":"Ross","year":"2012","journal-title":"Pediatr Cardiol"},{"key":"B17","first-page":"431","article-title":"Tailored assays for pharmacokinetic and pharmacodynamic investigations of aliskiren and enalapril in children: an application in serum, urine, and Saliva","volume":"20","author":"Burckhardt","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4155\/bio-2019-0242","article-title":"A comprehensive quality control system suitable for academic research: application in a pediatric study","volume":"12","author":"Makowski","year":"2020","journal-title":"Bioanalysis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/metabo9010012","article-title":"Direct infusion based metabolomics identifies metabolic disease in Patients\u2019 dried blood spots and plasma","volume":"9","author":"Haijes","year":"2019","journal-title":"Metabolites"},{"key":"B20","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12872-020-01579-x","article-title":"The relationship of plasma renin, angiotensin, and aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension","volume":"20","author":"Liu","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/metabo10110457","article-title":"Towards a more reliable identification of isomeric metabolites using pattern guided retention validation","volume":"10","author":"Opialla","year":"2020","journal-title":"Metabolites"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1007\/s11010-021-04159-5","article-title":"Comprehensive plasma metabolomic and lipidomic analyses reveal potential biomarkers for heart failure","volume":"476","author":"Zhou","year":"2021","journal-title":"Mol Cell Biochem"},{"key":"B23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1161\/01.HYP.37.2.308","article-title":"Signaling events mediating the additive effects of oleic acid and angiotensin II on vascular smooth muscle cell migration","volume":"37","author":"Greene","year":"2001","journal-title":"Hypertension"},{"key":"B24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1161\/01.HYP.31.4.978","article-title":"Oleic acid and angiotensin II induce a synergistic mitogenic response in vascular smooth muscle cells","volume":"31","author":"Lu","year":"1998","journal-title":"Hypertension"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1161\/01.RES.0000047506.52381.90","article-title":"Reduced myocardial and systemic L-arginine uptake in heart failure","volume":"91","author":"Kaye","year":"2002","journal-title":"Circ Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0002-8703(97)70253-9","article-title":"Increased renal formation of thromboxane A2 and prostaglandin F2 alpha in heart failure","volume":"133","author":"Castellani","year":"1997","journal-title":"Am Heart J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.cardfail.2005.08.005","article-title":"The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure","volume":"12","author":"Kotlyar","year":"2006","journal-title":"J Card Fail"},{"key":"B28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1161\/CIRCHEARTFAILURE.108.820217","article-title":"Heart failure in children: part I: history, etiology, and pathophysiology","volume":"2","author":"Hsu","year":"2009","journal-title":"Circ Heart Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fped.2018.00079","article-title":"Echocardiographic evaluation of ventricular function-for the neonatologist and pediatric intensivist","volume":"6","author":"Tissot","year":"2018","journal-title":"Front Pediatr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/nu11092092","article-title":"The emerging role of l-glutamine in cardiovascular health and disease","volume":"11","author":"Durante","year":"2019","journal-title":"Nutrients"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1039\/c3mb70227h","article-title":"Metabolomic identification of diagnostic plasma biomarkers in humans with chronic heart failure","volume":"9","author":"Wang","year":"2013","journal-title":"Mol Biosyst"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0124844","DOI":"10.1371\/journal.pone.0124844","article-title":"Metabolomic fingerprint of heart failure with preserved ejection fraction","volume":"10","author":"Zordoky","year":"2015","journal-title":"PLoS One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ajh.24491","article-title":"Glucosylsphingosine is a key biomarker of Gaucher disease","volume":"91","author":"Murugesan","year":"2016","journal-title":"Am J Hematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00726-009-0446-1","article-title":"Age-related changes of muscle and plasma amino acids in healthy children","volume":"39","author":"Hammarqvist","year":"2010","journal-title":"Amino Acids"},{"key":"B35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1042\/CS20160414","article-title":"Perspective on precision medicine in paediatric heart failure","volume":"131","author":"Fridman","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/CCM.0000000000000982","article-title":"Metabolic profiling of children undergoing surgery for congenital heart disease","volume":"43","author":"Correia","year":"2015","journal-title":"Crit Care Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11306-021-01846-8","article-title":"Metabolic profiles identify circulating biomarkers associated with heart failure in young single ventricle patients","volume":"17","author":"O'Connell","year":"2021","journal-title":"Metabolomics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e010711","DOI":"10.1161\/JAHA.118.010711","article-title":"Metabolomic fingerprinting of infants undergoing cardiopulmonary bypass: changes in metabolic pathways and association with mortality and cardiac intensive care unit length of stay","volume":"7","author":"Davidson","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B39","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/nbm.1395","article-title":"1H NMR metabolomics study of age profiling in children","volume":"22","author":"Gu","year":"2009","journal-title":"NMR Biomed"},{"key":"B40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/0929867324666171006151408","article-title":"Metabolomics and heart diseases: from basic to clinical approach","volume":"26","author":"Barba","year":"2019","journal-title":"Curr Med Chem"},{"key":"B41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12871-021-01301-0","article-title":"Effects of sevoflurane anesthesia and abdominal surgery on the systemic metabolome: a prospective observational study","volume":"21","author":"Wei","year":"2021","journal-title":"BMC Anesthesiol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1530063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:32:01Z","timestamp":1745818321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1530063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":41,"alternative-id":["10.3389\/fped.2025.1530063"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1530063","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"article-number":"1530063"}}